ELVN
Enliven Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$38.70
+3.70%Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- -$0.50
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- -$0.49
- EPS estimate
- -$0.39
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -0.4%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $76
- PT range
- $70 – $82
- Analysts
- 9
9 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 5, 2026 | -$0.39 | -$0.49 | Miss -26.56% | — |
| May 7, 2026 | -$0.44 | -$0.38 | Beat 13.64% | — |
| Mar 3, 2026 | -$0.42 | -$0.48 | Miss -14.29% | — |
| Nov 12, 2025 | -$0.43 | -$0.32 | Beat 25.58% | — |
| Aug 13, 2025 | -$0.53 | -$0.49 | Beat 7.55% | — |
| May 14, 2025 | -$0.51 | -$0.57 | Miss -11.76% | — |
| Mar 13, 2025 | -$0.53 | -$0.46 | Beat 13.21% | — |
| Mar 14, 2024 | -$0.56 | -$0.47 | Beat 16.07% | $440.0K |
| Nov 9, 2023 | -$0.49 | -$0.51 | Miss -4.08% | — |
| Aug 10, 2023 | -$0.40 | -$0.41 | Miss -2.50% | — |
| May 11, 2023 | -$0.67 | -$0.80 | Miss -19.40% | — |
| Feb 10, 2023 | -$0.79 | $1.23 | Beat 256.49% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026